(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one - CAS 101328-85-2
Catalog: |
BB000485 |
Product Name: |
(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one |
CAS: |
101328-85-2 |
Synonyms: |
(4R)-3-(4-aminophenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one; (4R)-3-(4-aminophenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one |
IUPAC Name: | (4R)-3-(4-aminophenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one |
Description: | (R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (CAS# 101328-85-2) is a metabolite of Levosimendan. |
Molecular Weight: | 203.24 |
Molecular Formula: | C11H13N3O |
Canonical SMILES: | CC1CC(=O)NN=C1C2=CC=C(C=C2)N |
InChI: | InChI=1S/C11H13N3O/c1-7-6-10(15)13-14-11(7)8-2-4-9(12)5-3-8/h2-5,7H,6,12H2,1H3,(H,13,15)/t7-/m1/s1 |
InChI Key: | GDMRFHZLKNYRRO-SSDOTTSWSA-N |
Density: | 1.309 g/cm3 |
MDL: | MFCD09032921 |
LogP: | 1.47450 |
Publication Number | Title | Priority Date |
US-2021177840-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | 20191216 |
CN-110885315-A | Preparation method of important intermediate of levosimendan | 20191213 |
US-2020330463-A1 | Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan | 20180821 |
CN-110831599-A | Compounds, compositions and methods for cancer treatment | 20170203 |
EP-3576742-A1 | Compounds, compositions and methods for cancer treatment | 20170203 |
PMID | Publication Date | Title | Journal |
22980396 | 20121101 | [Retrospective descriptive study about the use of levosimendan in children undergoing surgical correction for congenital heart disease] | Revista espanola de anestesiologia y reanimacion |
23034494 | 20121001 | Beneficial effects of levosimendan in infants with sepsis-associated cardiac dysfunction: report of 2 cases | Pediatric emergency care |
22249394 | 20120901 | Levosimendan infusion improves cardiac output but not blood pressure in a rodent model of severe metoprolol toxicity | Human & experimental toxicology |
22622649 | 20120901 | Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study | Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies |
21784540 | 20120823 | Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan | International journal of cardiology |
Complexity: | 280 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 1 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 203.105862047 |
Formal Charge: | 0 |
Heavy Atom Count: | 15 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 2 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 203.105862047 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 67.5 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 0.8 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Pyridazines
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS